RNAi Drug Delivery : Technologies and Gobal Markets - WTVM.com-Columbus, GA News Weather & Sports

RNAi Drug Delivery : Technologies and Gobal Markets

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Reportlinker

NEW YORK, July 7, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

RNAi Drug Delivery : Technologies and Gobal Markets

http://www.reportlinker.com/p02212007/RNAi-Drug-Delivery--Technologies-and-Gobal-Markets.html

This BCC Research report provides an in-depth assessment of recent progress and future opportunities for RNA interference (RNAi) players in major therapeutic and drug delivery areas, including infectious diseases, cancer, inflammation/immune dysfunction, central nervous system (CNS) disorders, and cardiology/metabolism. Known simply as RNAi, this field has rapidly emerged as a fast-growing new market. This report also provides forecasts for market growth through 2018 across RNAi market segments, reviews the latest advances in RNAi drug delivery technologies, and assesses the competitive landscape across RNAi therapeutic areas.

Use this report to:
- Receive information on importance of delivery for RNAi therapeutics.
- Identify the challenges to overcome in delivering RNAi.
- Identify the future trends of RNAi.
- Receive information on RNAi drug delivery strategies and current market dynamics.

Highlights
- The global market for RNAi drug delivery technologies reached nearly $9.3 billion in 2012 and nearly $11.7 billion in 2013 . This market is expected to grow to $38.8 billion in 2018, with a compound annual growth rate(CAGR) of 27.2% from 2013 to 2018.
- The nanoparticle delivery market reached $10.9 billion in 2013 and this market is expected to grow to $33.4 billion in 2018, with a CAGR of 25% from 2013 to 2018.
- The aptamer delivery market reached $218 million in 2013 and this market is expected to grow to $2.2 billion in 2018, with a CAGR of 58.2% from 2013 to 2018.

INTRODUCTION

STUDY GOALS AND OBJECTIVES
This BCC Research report, RNAI Drug Delivery: Technologies and Global Markets, provides an in-depth assessment of recent progress and future opportunities for RNA
interference (RNAi) players in major therapeutic and drug delivery areas, including infectious diseases, cancer, inflammation/immune dysfunction, central nervous system
(CNS) disorders, and cardiology/metabolism. The latest trends in RNAi therapeutics are examined, focusing on the main areas of clinical need, general/proprietary
technologies, and company pipelines, and the activities and strategies of RNAi-based therapeutic companies are profiled. This report also provides forecasts for market
growth to 2018 across RNAi market segments, reviews the latest advances in RNAi drug delivery technologies, and assesses the competitive landscape across RNAi
therapeutic areas.

REASONS FOR DOING THE STUDY
Since its discovery in 1998 by two scientists, the naturally occurring RNA interference effect has been hailed as the hottest technical breakthrough in biological research. It
may even surpass polymerase chain reaction (PCR) as a top technology. RNA interference allows scientists to silence the expression or effect of a gene being studied. Known simply as RNAi, this field has rapidly emerged as a fast-growing new market. This report assesses this emerging commercial market and maps the key RNAi therapeutic and drug delivery players on the market landscape. The initial companies produced reagents and kits for the biological research reagents market to support basic and applied research in academia, government, and industry. A number of companies decided to take the long road to develop therapeutics. Others have developed drug delivery approaches for emerging RNAi therapeutics. This report analyzes emerging RNAi molecules and delivery technologies and examines new molecular targets and pipeline drugs. It also evaluates competitors and collaborators in the developing RNAi technologies and examines the latest RNAi-related patenting trends.

SCOPE OF REPORT
The latest trends in RNAi therapeutics are examined, focusing on the main areas of clinical need, general/proprietary technologies, and company pipelines, and the
activities and strategies of RNAi-based developers are profiled. This report also provides forecasts for market growth to 2018 across major RNAi market segments. This report provides an in-depth assessment of recent progress and future opportunities for RNAi players in major therapeutic areas.

INTENDED AUDIENCE
This report is an exhaustive study on the worldwide RNAi therapeutic and drug delivery market, giving crucial statistics and analysis on the delivery technologies, market
structure, market size, key drug segments, important trends in technology development, major opportunities, and market shares of key players and drugs. This report may prove crucial for the firms or investors seeking engagement in the concerned sector. RNAi continues to offer significant promise for a host of therapeutic treatments. Potentially any disease-causing gene, cell type, or tissue can be targeted with RNAi, including those not "druggable" with small molecules or protein-based therapies. Pharma companies are increasingly investing in small interfering RNA (siRNA) optimization or examining siRNA alternatives in addition to staking out proprietary positions in lipid-based, nanotransporter-based, and alternative delivery technologies. The development and licensing of such platforms will become crucial for developers over the coming years.

METHODOLOGY
Primary and secondary research methodologies, as well as interviews with key players in the RNAi field were used in preparing this report. Secondary sources include books,
newspapers, trade journals, white papers, industry portals, government agencies, trade associations, monitoring industry news and developments, and through access to paid
databases. The base year of the report is 2013, with forecast data provided through 2018. Historical, base year and forecast data are provided for each market segment of
this report. Growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in research and
development (R&D), and current product growth, etc.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
SCOPE OF REPORT 2
INTENDED AUDIENCE 2
METHODOLOGY 3
RELATED BCC RESEARCH REPORTS 3
ANALYST'S CREDENTIALS 3
BCC RESEARCH WEBSITE 3
DISCLAIMER 4

CHAPTER 2 SUMMARY 6
SUMMARY TABLE GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES,
THROUGH 2018 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES,
2013-2018 ($ MILLIONS) 7

CHAPTER 3 OVERVIEW 10
OVERVIEW 10
WHAT IS RNAI? 12
RNAI AS THERAPY 12
THE PROMISE OF RNAI 13
TABLE 1 VARIOUS TECHNOLOGIES FOR GENE SUPPRESSION 13
RNAI TECHNOLOGY 14
RNAI MECHANISM: HOW DOES IT WORK? 15
WHY SIRNA THERAPEUTICS? 16
SIRNA DELIVERY 18
RNAI DESIGN AND METHODOLOGIES 18
Barriers to Delivery 19
Cellular Uptake and siRNAs 20
SiRNA Delivery and Challenges 20
COMMERCIAL INTEREST 21
LIPOSOME-BASED DELIVERY 22
NONLIPOSOMAL METHODS 22
Nucleic-acid Aptamers 22
Aptamers as Therapeutics 23
TABLE 2 THERAPEUTICALLY TARGETED APTAMERS 24
Aptamers for siRNA Delivery 25
Challenges: Aptamer-siRNA Delivery 26
Commercial Interest for Aptamers 28
Nanotechnology-based Delivery 28
Nanoparticles 29
Advantages 29
TABLE 3 REQUIRED STEPS FOR DEVELOPING EFFECTIVE RNAI DRUG 30
ANTISENSE THERAPY 30
Selected Companies 31
CLASSES OF ENDOGENOUS SMALL RNAS 31
siRNA 32
miRNA 33
OUTLOOK 33

CHAPTER 4 RNAI DRUG DELIVERY 36
RNAI DISCOVERED 36
IMPORTANCE OF DELIVERY FOR RNAI THERAPEUTICS 36
DRUG DELIVERY TECHNOLOGIES 37
TABLE 4 ROLE OF DRUG DELIVERY 38
NEED FOR NEW TECHNOLOGIES 38
RNAI DELIVERY-TOOL FOR DRUG DISCOVERY AND DEVELOPMENT 39
siRNA Screening 39
shRNA Screening 40
CHALLENGES TO OVERCOME IN DELIVERING RNAI 40
TABLE 5 DIFFERENT RNAI DELIVERY APPROACHES 41
DIFFERENT DELIVERY TECHNIQUES 41
VECTOR-BASED DELIVERY 41
VECTOR-BASED RNAI FOR IN VIVO RNAI EXPERIMENTS 42
TABLE 6 COMPANIES WITH PLASMID RNAI VECTORS 43
Viral Vectors for Delivery of siRNA 43
TABLE 7 RNAi VIRAL VECTOR DELIVERY METHODS 43
TABLE 8 LENTIVIRAL DELIVERY PRODUCTS AND COMPANIES 44
NONVIRAL SIRNA DELIVERY 44
Hydrodynamic IV Injection 44
Electroporation 44
Carrier-mediated Delivery 45
Lipid-based siRNA Delivery 45
Polymer-Based siRNA Delivery 46
Combined Lipid and Polymer Carriers for a Better siRNA Delivery 47
Peptide-Mediated siRNA Delivery 48
Antibody-Mediated siRNA Delivery 49
Dendrimer-Mediated siRNA Delivery 49
Stem-Cell-Based Delivery 50
Light Controllable Delivery of siRNA 50
PROPRIETARY DELIVERY PLATFORMS 50
SYSTEMIC DELIVERY STRATEGIES 52
TABLE 9 THERAPEUTIC STRATEGIES 52
LOCALIZED DELIVERY 53
Targeted Cellular Delivery 53
EXPRESSION-BASED STRATEGIES 55
RNAI DELIVERY AND IMPACT ON THERAPEUTIC DEVELOPMENTS 56
New Developments 57
Tissue Delivery 58
RNAi as Drugs 59
CURRENT NONBIOLOGICAL DELIVERY VEHICLES FOR SIRNAS 59
Simple Excipients 59
TABLE 10 SIMPLE EXCIEPIENTS FOR RNAI DELIVERY 60
TRANSFECTION TECHNIQUES 60
Electroporation 60
Conjugates 60
TABLE 11 CONJUGATES, PEPTIDES, AND PROTEINS, OTHERS 61
Peptides and Proteins 61
Dynamic Polyconjugate Transfection 61
Polymer Carriers/Nanoparticles 62
TABLE 12 POLYMER CARRIERS/NANOPARTICLES FOR RNAI DELIVERY 63
Liposomes and Lipoplexes 64
TABLE 13 LIPOSOMES/LIPOPLEXES AND RNAI DELIVERY 65
Case Study-siRNA in Mammalian Cells 65
Gene Silencing (RNAi) in Neuronal Cells 65
Concerns about RNAi Delivery 65
KEY COMPANIES 66
siRNA Transfection 66
TABLE 14 COMPANIES INVOLVED IN DRUG DELIVERY TECHNOLOGIES FOR SIRNA 67
Delivery as Particles or Complexes 67
Delivery with Modifications 68
SUMMARY 68

CHAPTER 5 RNAI-BASED THERAPEUTICS 71
RNAI-BASED THERAPEUTICS: THE EMERGING INDUSTRY LANDSCAPE 71
DELIVERING RNAI THERAPEUTICS 72
RNAi and Cancer Therapeutics 74
REGULATORY CONCERNS 74
RNAI IN CLINICAL TRIALS 75
Clinical Trials: RNAi 75
TABLE 15 THE GLOBAL RNA INTERFERENCE THERAPEUTIC PIPELINE 76
Other Candidates in Clinic 78
Terminated Programs 79
Other Programs 80
THERAPEUTIC RNAI DEVELOPMENTS 80
ALN-VSP02 80
Alnylam's ALN-RSV: Respiratory Syncytial Virus 82
ALN-RSV01 Treatment of Respiratory Syncytial Virus Infection in Lung
Transplant Patients 83
TABLE 16 RECENT UPDATES: RNAi CLINICAL TRIALS 84
TABLE 17 CLINICAL TRIALS: RNAI-SYSTEMIC DELIVERY 85
CHALLENGES: RNAI-BASED THERAPIES 87

CHAPTER 6 RNAI LANDSCAPE 90
FUTURE TRENDS 90
WHAT IS RNA INTERFERENCE? 90
Locked Nucleic Acid 91
RNAI AS A RESEARCH TOOL 91
THE IMPORTANCE OF RNAI DESIGN 91
FACTS AND TIMELINES 92
MARKET GROWTH 92
GLOBAL MARKET FOR RNAI 93
TABLE 18 GLOBAL RNAI RESEARCH SALES AND FORECAST, THROUGH 2018 ($
MILLIONS) 93
FIGURE 1 GLOBAL RNAI RESEARCH SALES, 2010-2018 ($ MILLIONS) 93
TABLE 19 GLOBAL TOOLS, REAGENTS AND THERAPEUTIC MARKET FOR RNAI,
THROUGH 2018 ($ MILLIONS) 94
FIGURE 2 GLOBAL TOTAL MARKET FOR RNAI, 2012-2018 ($ MILLIONS) 94
RNAI TECHNOLOGIES/PRODUCTS IN RESEARCH APPLICATIONS 95
RNAi Screening for Drug Discovery 96
Individual versus Pooled siRNAs 97
Necessary Controls 97
High-throughput siRNA Delivery 97
RNAI TOOL AND REAGENT MARKET 99
Transfection Products 100
Key Companies 100
TABLE 20 RNAi COMPANIES WITH TRANSFECTION REAGENTS 100
RNAi Reagents 101
Lipid Transfection 102
In Vivo Reagents and Therapeutics 102
RNAi Experiments in Animals 103
RNAI AND THERAPEUTICS 104
TABLE 21 IN VIVO DELIVERY 104
Viral-based Transfections 105
TABLE 22 VIRAL BASED DELIVERY TECHNOLOGIES 106
Other Methods 106
RNAi Reagents and Kits 107
TABLE 23 RNAI TOOL/REAGENT COMPANIES 108
KEY COMPANIES 109
Inc.Lonza 110
THE FUTURE OF RNAI THERAPEUTICS 110

CHAPTER 7 RNAI DRUG DELIVERY-MARKET DATA 112
MARKET TRENDS 112
MARKET SIZE AND GROWTH 112
RNAI DRUGS 113
GLOBAL PHARMACEUTICAL MARKET 113
TABLE 24 GLOBAL PHARMACEUTICAL SALES AND FORECAST THROUGH 2018 ($
BILLIONS) 114
FIGURE 3 GLOBAL PHARMACEUTICAL SALES AND FORECAST, 2011-2018 ($
BILLIONS) 114
Pharmaceutical Growth Rates 114
Emerging Markets 115
TABLE 25 TOTAL UNAUDITED AND AUDITED GLOBAL PHARMACEUTICAL MARKET
BY REGION, THROUGH 2017 ($ BILLIONS) 116
U.S. Pharmaceutical Industry 116
Global Pharmaceutical Companies 116
TABLE 26 TOP 25 PHARMACEUTICAL COMPANIES, GLOBAL SALES, 2012 AND 2013
($ MILLIONS) 117
TABLE 27 TWELVE LARGEST PHARMACEUTICAL COMPANIES 2010 ($ MILLIONS) 118
DRUG DELIVERY TECHNOLOGY LANDSCAPE 118
DRUG DELIVERY MARKET 119
Drug Delivery Technologies and Global Market 119
TABLE 28 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH
2018 ($ MILLIONS) 120
FIGURE 4 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($
MILLIONS) 120
TABLE 29 KEY PLAYERS: DRUG DELIVERY TECHNOLOGIES MARKET 122
European Drug Delivery Market 122
TABLE 30 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($
MILLIONS) 123
FIGURE 5 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($
MILLIONS) 123
Oral Drug Delivery 124
TABLE 31 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH
2018 ($ MILLIONS) 124
FIGURE 6 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2010-2018 ($
MILLIONS) 124
Implantable and Injectable Drug Delivery 125
TABLE 32 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH
2018 ($ MILLIONS) 125
FIGURE 7 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, 2011-2018
($ MILLIONS) 125
Transdermal Drug Delivery 127
TABLE 33 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET,
THROUGH 2018 ($ MILLIONS) 127
FIGURE 8 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET,
2011-2018 ($ MILLIONS) 127
Drug Delivery Market in the U.S. 128
TABLE 34 U.S. DRUG DELIVERY TECHNOLOGIES MARKET AND FORECAST
THROUGH 2018 ($ MILLIONS) 128
FIGURE 9 U.S. DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS) 128
PULMONARY DRUG DELIVERY 129
TABLE 35 TOP ASTHMA AND COPD DRUGS 129
TABLE 36 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH
2018 ($ MILLIONS) 130
FIGURE 10 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($
MILLIONS) 130
RNAI MARKET ANALYSIS 130
LEADING PLAYERS 131
Rxi Pharmaceuticals 131
Tekmira Pharmaceuticals 132
Arrowhead Research Corp. 132
RNAI MARKET DYNAMICS 133
RNAI NUCLEIC ACID DRUG DELIVERY 134
TABLE 37 GLOBAL NUCLEIC ACID DELIVERY TECHNOLOGIES MARKET, THROUGH
2018 ($ MILLIONS) 134
FIGURE 11 GLOBAL NUCLEIC ACID DELIVERY TECHNOLOGIES MARKET, 2010-2018
($ MILLIONS) 134
TABLE 38 GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2018 ($ MILLIONS) 136
FIGURE 12 GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2018 ($
MILLIONS) 137
NUCLEIC ACID APTAMER–BASED NANOPARTICLES 137
TARGETED DELIVERY 138
THE TOTAL NANOPARTICLE MARKET 138
TABLE 39 GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET,
THROUGH 2018 ($ MILLIONS) 138
FIGURE 13 GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET,
2012-2018 ($ MILLIONS) 139
DELIVERY OF THERAPEUTICS TO THE TARGET TISSUES 139
TABLE 40 GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH
2018 ($ MILLIONS) 139
FIGURE 14 GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES, MARKET,
2012-2018 ($ MILLIONS) 139
RNAI DELIVERY APPROACHES AND CURRENT DEVELOPMENTS 140
DEVELOPMENT OF RNAI-BASED THERAPEUTICS 141
NANOPARTICLE-BASED DELIVERY 142
RNAi Drugs under Investigation 143
TABLE 41 NON-VIRAL SIRNAS 143
LIPOSOME AND NANOPARTICLES 145
POLYMERS 146
CALANDO PHARMACEUTICALS 147
INTRADIGM 147
MESOPOROUS SILICA NANOPARTICLES 147
PROTEIN OR PEPTIDE-BASED NANOPARTICLES 148
BACTERIOPHAGE BASED NANOPARTICLES 149
SOLSTICE BIOLOGICS 150
GENZYME 150
TABLE 42 KEY RNAI COMPANIES 150
QUARK PHARMACEUTICALS 151
Marina Biotech 152
Lipid and Polymer-Based Systems 152
TABLE 43 LIPID-BASED TECHNOLOGIES-COMPANIES 152
TABLE 44 POLYMER-BASED AND LIPOSOMAL RNAi DELIVERY SYSTEMS (%) 153
RNAI INTO THE PATIENTS 154
ROCHE 154
Polyconjugate Technologies 154
Polymer-Based Systems-Limitations 155
RXi 156
TABLE 45 NANOPARTICLES TECHNOLOGIES-COMPANIES 156
Single siRNA Delivery 157
TABLE 46 SINGLE RNAi DELIVERY TECHNOLOGIES, COMPANIES 157
DICERNA PHARMACEUTICALS 158
CONCLUSIONS 159

CHAPTER 8 RNAI DRUG DELIVERY STRATEGIES AND CURRENT MARKET DYNAMICS 161
SYSTEMIC DELIVERY STRATEGIES 161
CHALLENGES WITH RNAI DRUG DELIVERY 162
RNAI THERAPEUTIC MARKET 162
TABLE 47 SELECTED RNAI-BASED DRUGS IN DEVELOPMENT 163
COMMERCIAL POTENTIAL OF RNAI 163
TABLE 48 COMMERCIAL POTENTIAL OF RNAI 163
RNAI'S THERAPEUTIC POTENTIAL 164
HOW DOES RNAI WORK? 165
RNAIS AND PRECLINICAL AND CLINICAL STUDIES 165
CEQ508 in Clinic 166
RNAi as a Therapy 167
GLOBAL MARKET OF THERAPEUTIC RNAI 167
RNAi Therapeutic Market to Play a Key Role by 2020 167
TABLE 49 GLOBAL MARKET FOR THERAPEUTIC RNAi, THROUGH 2018 ($ MILLIONS) 168
FIGURE 15 GLOBAL MARKET FOR THERAPEUTIC RNAi, 2013 AND 2018 ($ MILLIONS) 168
TABLE 50 RNAi THERAPEUTIC COMPANIES 169
Benitec's Clinical Program 170
TABLE 51 ONGOING RNAi CLINICAL TRIALS: NANOPARTICLE DRUG DELIVERY 171
MicroRNA and Market 171
MIRNA MARKET 172
TABLE 52 TOTAL MIRNA MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 173
FIGURE 16 TOTAL MIRNA MARKET AND FORECAST, 2013 AND 2018 ($ MILLIONS) 173
TABLE 53 TOTAL MIRNA MARKET SALES, 2008 (%) 174
RECENT DEVELOPMENTS 174
RNAI LICENSING DEALS 175
TABLE 54 MAJOR RNAI LICENSING DEALS, 2005-2010 177
TARGETED DELIVERY 179
TABLE 55 SYSTEMIC DELIVERY TECHNOLOGIES, COMPANIES 180
KEY THERAPEUTIC COMPANIES AND HISTORICAL DEVELOPMENTS 181
ALNYLAM 181
Takeda Alliance 182
Other Discovery and Development Alliances 182
Isis Collaboration 182
Novartis Broad Alliance 183
Product Alliances 184
Kyowa Hakko Kirin Alliance 184
Cubist Alliance 184
Government Funding 185
NIH Contract 185
TABLE 56 ALNYLAM: PIPELINE 186
TEKMIRA 187
Funding 188
Tekmira's LNP Technology 188
TKM-ApoB 189
TKM-PLK1 190
PHASE I/II TKM-PLK1 CLINICAL TRIAL 190
TKM-Ebola 191
Roche 192
Merck 192
Bristol-Myers Squibb 192
TABLE 57 TEKMIRA'S PIPELINE 17 192
HUMAN CLINICAL TRIAL OF TKM-EBOLA 193
RXI PHARMACEUTICALS 194
Pipeline 194
TABLE 58 RXi PHARMACEUTICALS' DEVELOPMENT PIPELINE 194
RXi 109 195
CONNECTIVE TISSUE GROWTH FACTOR (CTGF) AND SCARRING 196
Clinical Program 196
Phase 2 196
RXi Agreements 197
Philips 197
Other Collaborative Agreements 197
Scientific Achievements 198
NIH Grant 198
MARINA BIOTECH 198
Pipeline 199
TABLE 59 MARINA BIOTECH'S DEVELOPMENT PIPELINE 199
Revenue 199
Ongoing Collaborations 199
Beth Israel Deaconess Medical Center-Boston, Mass. 199
Institut Pasteur 200
University of British Columbia (UBC)/Vancouver Prostate Centre
(VPC) 200
University of Helsinki 200
TABLE 60 MARINA BIOTECH SELECTED COLLABORATIONS 200
CALANDO PHARMACEUTICALS 201
CALAA-01 201
ISIS PHARMACEUTICALS 202
Pipeline 202
TABLE 61 ISIS PHARMACEUTICALS DRUG DEVELOPMENT PIPELINE 202
Strategic Alliances 203
Pharmaceutical Partners 204
SILENCE THERAPEUTICS 204
Proprietary Delivery Technologies 204
Pipeline 205
TABLE 62 SILENCE THERAPEUTICS, DEVELOPMENT PIPELINE 205
Collaborations 206
Quark Pharmaceuticals 207
Clinical Studies 207
TABLE 63 QUARK PHARMACEUTICALS CURRENT CLINICAL TRIALS 208
Pipeline 208
TABLE 64 QUARK PHARMACEUTICALS-DEVELOPMENT PIPELINE, 2010 208
QPI-1002 209
ROCHE 209
MERCK 210
SIRNAOMICS 210
TABLE 65 SIRNA THERAPEUTIC PROGRAM 210
STP702 (FluQuit): siRNA Therapeutics against Influenza Infection
(Pandemic Flu) 211
STP601 (Acurita) siRNA Therapeutics for AMD and Retinopathy 211
STP705 (Cutasil) siRNA Therapeutics for Skin Scarless Wound Healing
(SSWH) 211
STP503 (Trisilensa) siRNA Therapeutics for Breast Cancer 212
ACCESS PHARMACEUTICALS 212
KEY MIRNA THERAPEUTIC COMPANIES 212
MIRNA THERAPEUTICS 212
Pipeline 213
TABLE 66 MIRNA, DEVELOPMENT PIPELINE 213
MRX34 214
REGULUS 214
Pipeline 214
TABLE 67 MIRNA PROGRAMS 215
LOCAL THERAPY 215
DRUG DELIVERY IN CANCER 216
RNAI MARKETPLACE CHALLENGES 217
RNAI'S GROWTH AND FUTURE 217
CONCLUSIONS 218

CHAPTER 9 COMPANY PROFILES 220
RNAI-DISCOVERY AND GROWTH 220
COMPANY PROFILES 221
ACCESS PHARMACEUTICALS 221
ALNYLAM PHARMACEUTICALS 221
AMBION 222
APARNABIO 223
ARMAGEN TECHNOLOGIES 223
ARROWHEAD RESEARCH 224
ASURAGEN 224
B-BRIDGE INTERNATIONAL 224
BIO-RAD LABORATORIES 225
CALANDO PHARMACEUTICALS 225
CLONTECH LABORATORIES 225
CYNTELLECT 226
DHARMACON 226
DICERNA PHARMACEUTICALS 227
GENECOPOEIA 227
GENETHERA 228
GENLANTIS 228
GENOSENSOR 228
GENERAL RESEARCH LABORATORY 229
IMGENEX 229
INTEGRATED DNA TECHNOLOGIES (IDT) 230
INVITROGEN 230
INVIVOGEN 230
ISIS PHARMACEUTICALS 231
MARINA BIOTECH 231
MERCK 232
MIRAGEN THERAPEUTICS 232
MIRNA THERAPEUTICS INC. 232
NEW ENGLAND BIOLABS 233
OPEN BIOSYSTEMS 233
ORIGENE TECHNOLOGIES 233
PANOMICS 234
PHASERX 234
PROMEGA CORP. 235
PRONAI THERAPEUTICS 235
QUARK PHARMACEUTICALS 235
REGULUS THERAPEUTICS 236
RXI PHARMACEUTICALS 236
SIGMA-ALDRICH 237
SILENCE THERAPEUTICS 237
SIRNAOMICS 238
SOLSTICE BIOLOGICS 239
SOMAGENICS 239
SYSTEM BIOSCIENCES 240
TACERE THERAPEUTICS 240
TEKMIRA PHARMACEUTICALS CORP. 241
COMPANY PROFILES-EUROPE 241
ACTIGENICS 241
AMAXA 242
CENIX BIOSCIENCE 242
EXIQON 242
GENOVIS 243
PROSENSA HOLDING 243
QIAGEN 243
RNAX 243
SANTARIS PHARMA 244
COMPANY PROFILES-ASIA-PACIFIC 244
ALPHAGEN 244
BENITEC 245
BIONEER 245
U.S. 245
CYTOPATHFINDER INC. INC. 245
GENESIS RESEARCH & DEVELOPMENT CORP. 246
KOKEN CO. LTD. 246
ONCOLYS BIOPHARMA INC. INC. 246
SHANGHAI GENEPHARMA CO. LTD. 247
SHANGHAI GENOMICS 247
TRANSGENE BIOTEK 247

CHAPTER 10 MARKET SHIFTS IN RNAI SPACE 249
INTELLECTUAL PROPERTY AND PATENT ASPECTS 249
TABLE 68 MAJOR RNAI COMPANIES IN THE U.S.- PATENT DISTRIBUTION 249
FUTURE DEVELOPMENTS 250
SOME SELECTED PATENTS 250
RNAI PLATFORMS 251
SIRNA LITIGATIONS 252
RECENT PATENT NEWS 253
TABLE 69 PATENTS 255
LICENSES FOR RNAI PATENTS 257
KEY COMPANIES AND PATENTS 258
ALNYLAM 258
RXI 258
ISIS 259
QUARK 259
BENITEC 259
PARTNERSHIPS, ALLIANCES, MERGERS AND ACQUISITIONS 260
ALNYLAM COLLABORATORS: SIGNIFICANT NEW ADVANCES IN RNAI
DELIVERY 261
ALNYLAM, MEDTRONIC, AND CHDI FOUNDATION 262
ALNYLAM AND TEKMIRA 263
CONCLUSIONS 264
CHAPTER 11 BIBLIOGRAPHY 266

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES,
THROUGH 2018 ($ MILLIONS) 7
TABLE 1 VARIOUS TECHNOLOGIES FOR GENE SUPPRESSION 13
TABLE 2 THERAPEUTICALLY TARGETED APTAMERS 24
TABLE 3 REQUIRED STEPS FOR DEVELOPING EFFECTIVE RNAI DRUG 30
TABLE 4 ROLE OF DRUG DELIVERY 38
TABLE 5 DIFFERENT RNAI DELIVERY APPROACHES 41
TABLE 6 COMPANIES WITH PLASMID RNAI VECTORS 43
TABLE 7 RNAI VIRAL VECTOR DELIVERY METHODS 43
TABLE 8 LENTIVIRAL DELIVERY PRODUCTS AND COMPANIES 44
TABLE 9 THERAPEUTIC STRATEGIES 52
TABLE 10 SIMPLE EXCIEPIENTS FOR RNAI DELIVERY 60
TABLE 11 CONJUGATES, PEPTIDES, AND PROTEINS, OTHERS 61
TABLE 12 POLYMER CARRIERS/NANOPARTICLES FOR RNAI DELIVERY 63
TABLE 13 LIPOSOMES/LIPOPLEXES AND RNAI DELIVERY 65
TABLE 14 COMPANIES INVOLVED IN DRUG DELIVERY TECHNOLOGIES FOR SIRNA 67
TABLE 15 THE GLOBAL RNA INTERFERENCE THERAPEUTIC PIPELINE 76
TABLE 16 RECENT UPDATES: RNAI CLINICAL TRIALS 84
TABLE 17 CLINICAL TRIALS: RNAI-SYSTEMIC DELIVERY 85
TABLE 18 GLOBAL RNAI RESEARCH SALES AND FORECAST, THROUGH 2018 ($
MILLIONS) 93
TABLE 19 GLOBAL TOOLS, REAGENTS AND THERAPEUTIC MARKET FOR RNAI,
THROUGH 2018 ($ MILLIONS) 94
TABLE 20 RNAI COMPANIES WITH TRANSFECTION REAGENTS 100
TABLE 21 IN VIVO DELIVERY 104
TABLE 22 VIRAL BASED DELIVERY TECHNOLOGIES 106
TABLE 23 RNAI TOOL/REAGENT COMPANIES 108
TABLE 24 GLOBAL PHARMACEUTICAL SALES AND FORECAST THROUGH 2018 ($
BILLIONS) 114
TABLE 25 TOTAL UNAUDITED AND AUDITED GLOBAL PHARMACEUTICAL MARKET BY
REGION, THROUGH 2017 ($ BILLIONS) 116
TABLE 26 TOP 25 PHARMACEUTICAL COMPANIES, GLOBAL SALES, 2012 AND 2013 ($
MILLIONS) 117
TABLE 27 TWELVE LARGEST PHARMACEUTICAL COMPANIES 2010 ($ MILLIONS) 118
TABLE 28 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018
($ MILLIONS) 120
TABLE 29 KEY PLAYERS: DRUG DELIVERY TECHNOLOGIES MARKET 122
TABLE 30 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018 ($
MILLIONS) 123
TABLE 31 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH 2018
($ MILLIONS) 124
TABLE 32 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, THROUGH
2018 ($ MILLIONS) 125
TABLE 33 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET,
THROUGH 2018 ($ MILLIONS) 127
TABLE 34 U.S. DRUG DELIVERY TECHNOLOGIES MARKET AND FORECAST THROUGH
2018 ($ MILLIONS) 128
TABLE 35 TOP ASTHMA AND COPD DRUGS 129
TABLE 36 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, THROUGH 2018
($ MILLIONS) 130
TABLE 37 GLOBAL NUCLEIC ACID DELIVERY TECHNOLOGIES MARKET, THROUGH
2018 ($ MILLIONS) 134
TABLE 38 GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2018 ($ MILLIONS) 136
TABLE 39 GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET,
THROUGH 2018 ($ MILLIONS) 138
TABLE 40 GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES MARKET, THROUGH
2018 ($ MILLIONS) 139
TABLE 41 NON-VIRAL SIRNAS 143
TABLE 42 KEY RNAI COMPANIES 150
TABLE 43 LIPID-BASED TECHNOLOGIES-COMPANIES 152
TABLE 44 POLYMER-BASED AND LIPOSOMAL RNAI DELIVERY SYSTEMS (%) 153
TABLE 45 NANOPARTICLES TECHNOLOGIES-COMPANIES 156
TABLE 46 SINGLE RNAI DELIVERY TECHNOLOGIES, COMPANIES 157
TABLE 47 SELECTED RNAI-BASED DRUGS IN DEVELOPMENT 163
TABLE 48 COMMERCIAL POTENTIAL OF RNAI 163
TABLE 49 GLOBAL MARKET FOR THERAPEUTIC RNAI, THROUGH 2018 ($ MILLIONS) 168
TABLE 50 RNAI THERAPEUTIC COMPANIES 169
TABLE 51 ONGOING RNAI CLINICAL TRIALS: NANOPARTICLE DRUG DELIVERY 171
TABLE 52 TOTAL MIRNA MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS) 173
TABLE 53 TOTAL MIRNA MARKET SALES, 2008 (%) 174
TABLE 54 MAJOR RNAI LICENSING DEALS, 2005-2010 177
TABLE 55 SYSTEMIC DELIVERY TECHNOLOGIES, COMPANIES 180
TABLE 56 ALNYLAM: PIPELINE 186
TABLE 57 TEKMIRA'S PIPELINE 17 192
TABLE 58 RXI PHARMACEUTICALS' DEVELOPMENT PIPELINE 194
TABLE 59 MARINA BIOTECH'S DEVELOPMENT PIPELINE 199
TABLE 60 MARINA BIOTECH SELECTED COLLABORATIONS 200
TABLE 61 ISIS PHARMACEUTICALS DRUG DEVELOPMENT PIPELINE 202
TABLE 62 SILENCE THERAPEUTICS, DEVELOPMENT PIPELINE 205
TABLE 63 QUARK PHARMACEUTICALS CURRENT CLINICAL TRIALS 208
TABLE 64 QUARK PHARMACEUTICALS-DEVELOPMENT PIPELINE, 2010 208
TABLE 65 SIRNA THERAPEUTIC PROGRAM 210
TABLE 66 MIRNA, DEVELOPMENT PIPELINE 213
TABLE 67 MIRNA PROGRAMS 215
TABLE 68 MAJOR RNAI COMPANIES IN THE U.S.- PATENT DISTRIBUTION 249
TABLE 69 PATENTS 255

LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FOR RNAI DRUG DELIVERY TECHNOLOGIES,
2013-2018 ($ MILLIONS) 7
FIGURE 1 GLOBAL RNAI RESEARCH SALES, 2010-2018 ($ MILLIONS) 93
FIGURE 2 GLOBAL TOTAL MARKET FOR RNAI, 2012-2018 ($ MILLIONS) 94
FIGURE 3 GLOBAL PHARMACEUTICAL SALES AND FORECAST, 2011-2018 ($ BILLIONS) 114
FIGURE 4 TOTAL GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($
MILLIONS) 120
FIGURE 5 GLOBAL DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($
MILLIONS) 123
FIGURE 6 GLOBAL ORAL DRUG DELIVERY TECHNOLOGIES MARKET, 2010-2018 ($
MILLIONS) 124
FIGURE 7 GLOBAL IMPLANTABLE/INJECTABLE DRUG DELIVERY MARKET, 2011-2018
($ MILLIONS) 125
FIGURE 8 GLOBAL TRANSDERMAL DRUG DELIVERY TECHNOLOGIES MARKET,
2011-2018 ($ MILLIONS) 127
FIGURE 9 U.S. DRUG DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($ MILLIONS) 128
FIGURE 10 GLOBAL PULMONARY DELIVERY TECHNOLOGIES MARKET, 2011-2018 ($
MILLIONS) 130
FIGURE 11 GLOBAL NUCLEIC ACID DELIVERY TECHNOLOGIES MARKET, 2010-2018 ($
MILLIONS) 134
FIGURE 12 GLOBAL APTAMERS THERAPEUTIC MARKET, THROUGH 2018 ($ MILLIONS) 137
FIGURE 13 GLOBAL NANOPARTICLE DRUG DELIVERY TECHNOLOGIES MARKET,
2012-2018 ($ MILLIONS) 139
FIGURE 14 GLOBAL TARGETED DRUG DELIVERY TECHNOLOGIES, MARKET,
2012-2018 ($ MILLIONS) 139
FIGURE 15 GLOBAL MARKET FOR THERAPEUTIC RNAI, 2013 AND 2018 ($ MILLIONS) 168
FIGURE 16 TOTAL MIRNA MARKET AND FORECAST, 2013 AND 2018 ($ MILLIONS) 173

To order this report: RNAi Drug Delivery : Technologies and Gobal Markets
http://www.reportlinker.com/p02212007/RNAi-Drug-Delivery--Technologies-and-Gobal-Markets.html

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

1909 Wynnton Road
Columbus, Ga. 31906

FCC Public File
publicfile@wtvm.com
706-494-5400
EEO Report
Closed Captioning

All content © Copyright 2000 - 2014 Worldnow and WTVM. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.